基因测试公司23andMe探索销售,因为它因金融斗争而裁员并结束治疗业务。 Genetic testing firm 23andMe explores sale as it cuts jobs and ends therapeutics business due to financial struggles.

23andMe基因测试公司正在探索战略替代办法,包括可能的销售或商业组合,因为它面临流动性问题,其股票价值大幅下降。 Genetic testing company 23andMe is exploring strategic alternatives, including a potential sale or business combination, as it faces liquidity concerns and a significant drop in its stock value. 该公司报告第三季度收入下降8%,计划削减40%的劳动力,结束治疗业务,以节省成本。 The company reported a third-quarter revenue decline of 8%, and it plans to cut 40% of its workforce and end its therapeutics business to save costs. 尽管非经常性研究服务暂时增加了收入,但23andMe的现金储备已降至7 940万美元,令人怀疑它能否继续作为一个持续经营的企业。 Despite a temporary revenue boost from non-recurring research services, 23andMe's cash reserves have dropped to $79.4 million, raising doubts about its ability to continue as a going concern.